Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer

Tony N. Talebi, Murugesan Manoharan, Rakesh Singal

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Patients with metastatic hormone-refractory prostate carcinoma may have dramatic and life-threatening coagulation complications from their disease. They are at risk for either clotting or bleeding events. We report the case of a man with metastatic castration-resistant prostate cancer with disseminated intravascular coagulation who had both clotting and bleeding in addition to thrombocytopenia. The patient did not respond to supportive therapy and was treated with docetaxel despite a platelet count of 46/mm. The treatment resulted in resolution of disseminated intravascular coagulation, normalization of the platelet count, and resolution of hematuria. We review disseminated intravascular coagulation in prostate cancer and different possible treatments.

Original languageEnglish
JournalAmerican Journal of Therapeutics
Volume19
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

docetaxel
Disseminated Intravascular Coagulation
Thrombocytopenia
Prostatic Neoplasms
Platelet Count
Drug Therapy
Hemorrhage
Castration
Hematuria
Prostate
Therapeutics
Hormones
Carcinoma

Keywords

  • disseminated intravascular coagulation
  • docetaxel
  • hematuria
  • prostate cancer
  • thrombocytopenia

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer. / Talebi, Tony N.; Manoharan, Murugesan; Singal, Rakesh.

In: American Journal of Therapeutics, Vol. 19, No. 1, 01.01.2012.

Research output: Contribution to journalArticle

@article{b02ccc43c15a49ae8a443b2259a50bbe,
title = "Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer",
abstract = "Patients with metastatic hormone-refractory prostate carcinoma may have dramatic and life-threatening coagulation complications from their disease. They are at risk for either clotting or bleeding events. We report the case of a man with metastatic castration-resistant prostate cancer with disseminated intravascular coagulation who had both clotting and bleeding in addition to thrombocytopenia. The patient did not respond to supportive therapy and was treated with docetaxel despite a platelet count of 46/mm. The treatment resulted in resolution of disseminated intravascular coagulation, normalization of the platelet count, and resolution of hematuria. We review disseminated intravascular coagulation in prostate cancer and different possible treatments.",
keywords = "disseminated intravascular coagulation, docetaxel, hematuria, prostate cancer, thrombocytopenia",
author = "Talebi, {Tony N.} and Murugesan Manoharan and Rakesh Singal",
year = "2012",
month = "1",
day = "1",
doi = "10.1097/MJT.0b013e3181e1cb8c",
language = "English",
volume = "19",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer

AU - Talebi, Tony N.

AU - Manoharan, Murugesan

AU - Singal, Rakesh

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Patients with metastatic hormone-refractory prostate carcinoma may have dramatic and life-threatening coagulation complications from their disease. They are at risk for either clotting or bleeding events. We report the case of a man with metastatic castration-resistant prostate cancer with disseminated intravascular coagulation who had both clotting and bleeding in addition to thrombocytopenia. The patient did not respond to supportive therapy and was treated with docetaxel despite a platelet count of 46/mm. The treatment resulted in resolution of disseminated intravascular coagulation, normalization of the platelet count, and resolution of hematuria. We review disseminated intravascular coagulation in prostate cancer and different possible treatments.

AB - Patients with metastatic hormone-refractory prostate carcinoma may have dramatic and life-threatening coagulation complications from their disease. They are at risk for either clotting or bleeding events. We report the case of a man with metastatic castration-resistant prostate cancer with disseminated intravascular coagulation who had both clotting and bleeding in addition to thrombocytopenia. The patient did not respond to supportive therapy and was treated with docetaxel despite a platelet count of 46/mm. The treatment resulted in resolution of disseminated intravascular coagulation, normalization of the platelet count, and resolution of hematuria. We review disseminated intravascular coagulation in prostate cancer and different possible treatments.

KW - disseminated intravascular coagulation

KW - docetaxel

KW - hematuria

KW - prostate cancer

KW - thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=84855681352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855681352&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181e1cb8c

DO - 10.1097/MJT.0b013e3181e1cb8c

M3 - Article

VL - 19

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 1

ER -